Skip to main content
Policy Snapshot

May 16, 2024

The Centers for Medicare & Medicaid Services (CMS) has posted the 2024 Quality Measure Development Plan (MDP) Annual Report, which describes progress in developing clinician quality measures to support the Quality Payment Program (QPP).

The 2024 report records fiscal year (FY) 2023 expenditures of $1.1 million for measure development funded by title XVIII of the Act, including:

  • $161,077 to complete Adult COVID-19 Vaccination Status, a general medicine/crosscutting process measure

And in ongoing development:

  • $82,621 for one outcome measure
  • $94,710 for one patient engagement/experience measure
  • $364,089 for one patient-reported outcome performance measure
  • $399,425 for one process measure being developed as an electronic clinical quality measure (eCQM)

The 2024 MDP Annual Report summarizes cumulative spending of $62.6 million authorized by section 1848(s)(6) of the Social Security Act, as added by section 102 of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). The current inventory of 198 quality measures described in the report includes 11 of the 36 quality measures developed with MACRA funding from FY 2016 through FY 2022.

With those appropriations expiring, this is the eighth and final annual report. CMS will continue to track measure development activities and related expenditures internally to support the QPP.

Visit the Quality Payment Program Measure Development webpage for more information about the 2024 MDP Annual Report.